Johnson & Johnson $JNJ Shares Bought by Private Client Services LLC

Private Client Services LLC raised its holdings in Johnson & Johnson (NYSE:JNJ) by 11.2% during the second quarter, HoldingsChannel.com reports. The firm owned 1,816 shares of the company’s stock after buying an additional 183 shares during the period. Private Client Services LLC’s holdings in Johnson & Johnson were worth $277,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC raised its position in shares of Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after acquiring an additional 6,332 shares in the last quarter. Hudson Value Partners LLC grew its stake in Johnson & Johnson by 2.5% during the 4th quarter. Hudson Value Partners LLC now owns 41,403 shares of the company’s stock worth $5,648,000 after buying an additional 1,022 shares during the last quarter. Shell Asset Management Co. grew its stake in Johnson & Johnson by 6.2% during the 4th quarter. Shell Asset Management Co. now owns 10,725 shares of the company’s stock worth $1,551,000 after buying an additional 630 shares during the last quarter. Scissortail Wealth Management LLC grew its stake in Johnson & Johnson by 5,251.2% during the 4th quarter. Scissortail Wealth Management LLC now owns 21,726 shares of the company’s stock worth $3,142,000 after buying an additional 21,320 shares during the last quarter. Finally, Safe Harbor Fiduciary LLC grew its stake in Johnson & Johnson by 1.7% during the 4th quarter. Safe Harbor Fiduciary LLC now owns 6,152 shares of the company’s stock worth $890,000 after buying an additional 100 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.16% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts recently commented on JNJ shares. Bank of America upped their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the stock a “neutral” rating in a research note on Thursday, July 17th. Citigroup upped their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “buy” rating in a research note on Thursday, August 21st. Morgan Stanley upped their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 17th. Piper Sandler restated an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Finally, UBS Group increased their price target on Johnson & Johnson from $180.00 to $190.00 and gave the stock a “buy” rating in a research note on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $176.29.

Johnson & Johnson Trading Down 0.2%

NYSE:JNJ opened at $178.10 on Friday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $181.16. The stock has a market cap of $428.93 billion, a price-to-earnings ratio of 19.05, a PEG ratio of 2.27 and a beta of 0.40. The business has a fifty day moving average of $170.81 and a 200-day moving average of $161.29. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. During the same quarter in the prior year, the business posted $2.82 earnings per share. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were paid a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.9%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.